Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Exploratory, 28-Day Study to Examine the Effects of AR9281 on Blood Pressure and Glucose Tolerance in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00847899

Enrollment

150

Registered

2009-02-19

Start date

2009-01-31

Completion date

2009-11-30

Last updated

2009-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Impaired Glucose Tolerance

Keywords

hypertension, impaired glucose tolerance, s-EH enzyme inhibition, pre-diabetes

Brief summary

The purpose of this study is to determine the safety and efficacy of AR9281, a novel s-EH enzyme inhibitor, in improving glucose metabolism and blood pressure in patients with impaired glucose tolerance and mild to moderate hypertension.

Interventions

DRUGAR9281

AR9281 taken in BID dosing regimen for 28 days

DRUGPlacebo

Placebo taken in BID dosing regimen for 28 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* mild to moderate hypertension * naive to antihypertensive medication or on two or less antihypertensive medications * impaired glucose tolerance * mild obesity

Exclusion criteria

* Diagnosis of Type 1 or Type 2 diabetes * History of severe heart failure * AST, ALT levels more than twice the normal range

Design outcomes

Primary

Measure	Time frame
Systolic and Diastolic blood pressure	28 day treatment period
Glucose dynamics and insulin sensitivity	28 day treatment period

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026